ALNOV:EPA
Novacyt SA
ā§Ļ.ā§Ēā§ĢâŦ
ā§Ļ.ā§Ļā§Ļ%
(ā§Ļ.ā§Ļā§Ļ) ā§§ āĻĻāĻŋ
ā§§ā§Ŧ āύāĻā§, ā§Ģ:ā§Šā§Ģ:ā§§ā§ PM GMT +ā§§ · EUR
search
āϏāĻŦ āϏāĻŋāĻŽā§āĻŦāϞ
| āϏāĻŋāĻŽā§āĻŦāϞ | āĻĻāĻžāĻŽ | āĻĒāϰāĻŋāĻŦāϰā§āϤāύ āĻāϰā§āύ | % āĻĒāϰāĻŋāĻŦāϰā§āϤāύ |
|---|
insights_autoALNOV-āĻāϰ āĻāύā§āϝ āϏā§āϰāĻž āĻāύāϏāĻžāĻāĻ āĻā§āύāĻžāϰā§āĻ āĻāϰāĻž āĻšāĻā§āĻā§...
āĻā§āϞā§āύ
ā§Ļ.ā§Ēā§ĢâŦ
āϏāϰā§āĻŦāĻžāϧāĻŋāĻ
ā§Ļ.ā§Ēā§ĢâŦ
āϏāϰā§āĻŦāύāĻŋāĻŽā§āύ
ā§Ļ.ā§Ēā§ĒâŦ
āĻŽāĻžāϰā§āĻā§āĻ āĻā§āϝāĻžāĻĒ
ā§Š.⧍ā§Â āĻā§
āĻ
ā§āϝāĻžāĻāĻžāϰā§āĻ āĻāϞāĻŋāĻāĻŽ
ā§§.ā§Ŧā§§Â āϞāĻž
āĻāϞāĻŋāĻāĻŽ
ā§Ē.ā§Ŧā§Ē āϞāĻž
ā§Ģ⧍ āϏāĻĒā§āϤāĻžāĻšā§āϰ āϏāϰā§āĻŦā§āĻā§āĻ āĻĻāĻžāĻŽ
ā§§.ā§Ļā§ĒâŦ
ā§Ģ⧍ āϏāĻĒā§āϤāĻžāĻšā§āϰ āϏāϰā§āĻŦāύāĻŋāĻŽā§āύ āĻĻāĻžāĻŽ
ā§Ļ.⧍⧝âŦ
EPS
-ā§Ļ.ā§Šā§ŽâŦ
āĻāĻāĻāϏā§āĻā§āϝāĻžāύā§āĻĄāĻŋāĻ āĻļā§ā§āĻžāϰ
ā§.⧍ā§Ŧ āĻā§
āĻāϰā§āĻŽā§āϏāĻāĻā§āϝāĻž
ā§¨ā§¨ā§Ž
āĻā§āϞā§āύ
ā§Ļ.ā§Ēā§ĢâŦ
āϏāϰā§āĻŦāĻžāϧāĻŋāĻ
ā§Ļ.ā§Ēā§ĢâŦ
āϏāϰā§āĻŦāύāĻŋāĻŽā§āύ
ā§Ļ.ā§Ēā§ĒâŦ
āĻŽāĻžāϰā§āĻā§āĻ āĻā§āϝāĻžāĻĒ
ā§Š.⧍ā§Â āĻā§
āĻ
ā§āϝāĻžāĻāĻžāϰā§āĻ āĻāϞāĻŋāĻāĻŽ
ā§§.ā§Ŧā§§Â āϞāĻž
āĻāϞāĻŋāĻāĻŽ
ā§Ē.ā§Ŧā§Ē āϞāĻž
ā§Ģ⧍ āϏāĻĒā§āϤāĻžāĻšā§āϰ āϏāϰā§āĻŦā§āĻā§āĻ āĻĻāĻžāĻŽ
ā§§.ā§Ļā§ĒâŦ
ā§Ģ⧍ āϏāĻĒā§āϤāĻžāĻšā§āϰ āϏāϰā§āĻŦāύāĻŋāĻŽā§āύ āĻĻāĻžāĻŽ
ā§Ļ.⧍⧝âŦ
EPS
-ā§Ļ.ā§Šā§ŽâŦ
āĻāĻāĻāϏā§āĻā§āϝāĻžāύā§āĻĄāĻŋāĻ āĻļā§ā§āĻžāϰ
ā§.⧍ā§Ŧ āĻā§
āĻāϰā§āĻŽā§āϏāĻāĻā§āϝāĻž
ā§¨ā§¨ā§Ž
āĻāĻŦāϰā§āϰ āϏā§āĻā§āϰāĻŋ
āĻā§ā§āĻŦ āϏā§āϰā§āϏ āĻ āĻāĻŦāϰā§āϰ āĻĒāĻžāϰā§āĻāύāĻžāϰāĻĻā§āϰ āĻĨā§āĻā§
ChartMill
·
ā§Ē⧍ āĻŽāĻŋāύāĻŋāĻ āĻāĻā§
S&P 500 Top Movers: Gainers and Losers for Nov. 16, 2026
Investing.com
·
ā§Ģā§Ļ āĻŽāĻŋāύāĻŋāĻ āĻāĻā§
Why is SPDR S&P 500 ETF sliding today?
The Motley Fool
·
ā§§ā§§ āĻŽāĻŋāύāĻŋāĻ āĻāĻā§
Here's How the S&P 500 Has Moved the Day After Each of Nvidia's Last 12 Reports
Stocktwits
·
ā§Š āĻāĻŖā§āĻāĻž āĻāĻā§
Morgan Stanleyâs Mike Wilson Is Bullish On S&P 500 With A 15% Upside View For 2027
āĻĒā§āϰā§āĻĢāĻžāĻāϞ
Novacyt Group is an Anglo-French biotechnology group focused on clinical diagnostics, with offices in Camberley, Surrey, United Kingdom and VÊlizy-Villacoublay, France. The company produces in vitro and molecular diagnostic tests, supplying assays and reagents worldwide. Its business units include Primerdesign, Microgen Bioproducts and Lab21 Healthcare.
In January 2020 the company announced that its molecular diagnostics division, Primerdesign, had launched a molecular test for the 2019 strain of SARSr-CoV. The test was approved as eligible for procurement under the World Health Organization's Emergency Use Listing process in April 2020, meaning that the test could be supplied by the United Nations and other procurement agencies supporting the COVID-19 response. In the same month Novacyt announced a collaboration with AstraZeneca, GlaxoSmithKline and the University of Cambridge to support the UK in its COVID-19 national screening programme at a new testing laboratory at the university's Anne McLaren laboratory. Wikipedia
Novacyt SA āϏāĻŽā§āĻĒāϰā§āĻā§
āϏāĻŋāĻāĻāĻĄā§āĻāĻŋāĻĄ āĻ
ā§āϝāĻžāϞāĻŽāύā§āĻĄ
āĻāϰā§āĻŽā§ā§¨ā§¨ā§Ž
āĻĒā§āϰāϤāĻŋāώā§āĻ āĻžāϰ āϤāĻžāϰāĻŋāĻā§Š āĻā§āϞ, ⧍ā§Ļā§Ļā§Ŧ
āĻšā§āĻĄāĻā§ā§āĻžāϰā§āĻāĻžāϰ-
āϏā§āĻā§āĻāϰHealth Care
āĻāύā§āĻĄāĻžāϏā§āĻā§āϰāĻŋ-
āĻā§ā§āĻŦāϏāĻžāĻāĻnovacyt.com